𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Management of Refractory Acute Myeloid Leukemia: Re-induction Therapy or Straight to Transplantation?

✍ Scribed by E. J. Feldman; Usama Gergis

Book ID
107540324
Publisher
Current Science Inc.
Year
2011
Tongue
English
Weight
94 KB
Volume
7
Category
Article
ISSN
1558-8211

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Failure of lithium to reduce period of n
Failure of lithium to reduce period of neutropenia during induction therapy of acute myeloid leukemia
✍ J. Howard Scarffe; James Chang πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 384 KB πŸ‘ 1 views

Fifty-four patients treated with daunorubicin, cytosine arabinoside and thioquanine for acute myeloid leukemia were randomly assigned to recieve oral lithium carbonate 1200 mg daily or no lithium. The duration of neutropenia (<0.5 x 109/L) was similar between controls (median 22.5 days) and patients

Results of imatinib mesylate therapy in
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated